IRIG: Incretin Safety in JAMA

07/20/2007 06:34
Incretin are defined as a hormone produced in the gastrointestinal tract in response to food (especialy carbohydrates) intake, and stimulating insulin secretion in the presence of glucose. Presently, there are are two such hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Since incretin is able to reduce blood glucose and increase insulin sensitivity, GLP-1 has been a pharmalogical target in the control of glucose in clinics. Safety of GLP-1 analogues and GLP-1 enhancer (Dipeptidyl peptidase 4 inhibitors) has been a concern. In the current issue of JAMA, this issue is addressed in a review article. The conclusion is that "Glucagonlike peptide 1 analogues had more gastrointestinal side effects (risk ratio, 2.9 [95% CI, 2.0-4.2] for nausea and 3.2 [95% CI, 2.5-4.4] for vomiting). Dipeptidyl peptidase 4 inhibitors had an increased risk of infection". See detail in attached paper. 
 
By Jianping at PBRC

---------------------------------------
 
Jianping Ye, MD
Professor of Molecular Biology
Pennington Biomedical Research Center
Louisiana State University System
6400 Perkins Road
Baton Rouge, LA 70808
Phone: (225) 763-3163
Fax: (225) 763-2525
E-mail: yej@pbrc.edu
|